Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.58 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27652942 | 0.88 | NPC1 (0.83) | NPC1RAB9APOLBTSHRTAS1R3 | |
| SCHEMBL12995570 | 0.87 | POLB (0.69) | NPC1RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL11925392 | 0.87 | KMT2A (0.71) | NPC1RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL4391646 | 0.85 | POLB (0.71) | NPC1RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL6037506 | 0.84 | RAB9A (0.96) | NPC1RAB9ATSHRTAS1R3TAS1R1 | |
| SCHEMBL654537 | 0.83 | POLB (0.69) | NPC1RAB9APOLBTAS1R3TAS1R1 | |
| SCHEMBL2054569 | 0.83 | KMT2A (0.71) | NPC1RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL656477 | 0.83 | RAB9A (0.71) | NPC1RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL30576750 | 0.83 | POLB (0.59) | NPC1RAB9APOLBTSHRMAPT | |
| SCHEMBL16178505 | 0.83 | RAB9A (0.57) | NPC1RAB9APOLBTSHRTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221633-A | TRPV1/URAT1 dual inhibitor, preparation method and application thereof | 郑州大学第一附属医院 | 2024-06-21 | — | — | CN | claimed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | claimed |
| CN-122079899-A | Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4678234-A1 | ANTAGONIST HETEROCYCLIC COMPOUNDS INVOLVED IN THE CGAS-STING ROUTE | Centre National de la Recherche Scientifique (FR) | 2026-01-14 | — | — | EP | disclosed |
| CN-118221633-A | TRPV1/URAT1 dual inhibitor, preparation method and application thereof | 郑州大学第一附属医院 | 2024-06-21 | — | — | CN | disclosed |
| CN-116829542-A | Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient | 韩国化学研究院 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | disclosed |
| EP-2421838-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | NPC1 1156/4885RAB9A 3131/4885POLB 3294/4885 |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | NPC1 231/4885RAB9A 130/4885POLB 4438/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | NPC1 1968/4885RAB9A 1399/4885POLB 296/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | NPC1 1156/4885RAB9A 3131/4885POLB 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.